Faced with the complex dysregulation of the PI3K/Akt/mTOR pathway and the unique challenges it poses to existing therapies in IR/MASH-driven HCC, developing mechanism-based precision combination strategies is urgently needed. This evidence concerns the gene MTOR and hepatocellular carcinoma.